Skip to content
Study details
Enrolling now

Ketamine and Propofol NeuroImaging Trial

Keith M Vogt
NCT IDNCT07294092ClinicalTrials.gov data as of Apr 2026
Phase

EARLY_PHASE1

Target enrollment

60

Study length

about 2.4 years

Ages

18–59

Locations

1 site in PA

About this study

This trial is testing how ketamine and propofol affect brain activity using MRI and EEG scans. The goal is to understand changes in brain connectivity related to memory formation and pain perception during anesthesia.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Ketamine
  • 2.Take Propofol
  • 3.Use Peripheral Nerve Stimulation
PhaseEARLY_Phase 1
DrugKetamine
Primary goalPain intensity and unpleasantness ratings, comparing single-drug to drug-combination condition

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low12%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

ketamine (NMDA receptor antagonist; induces dissociative anesthesia and analgesia), propofol (Facilitates GABA; induces unconsciousness)

Drug routes

injection (Injection)

Endpoints

Primary: Pain intensity and unpleasantness ratings, comparing single-drug to drug-combination condition

Secondary: MRI-based activation during memory formation, comparing the single-drug condition to the combination-drug condition, MRI-based activation during painful stimulation, comparing the single-drug condition to the combination-drug condition, MRI-based changes in functional connectivity, comparing the single-drug condition to the combination-drug condition

Devices

therapeutic